Soleno Therapeutics Q2 EPS $(0.57) Beats $(0.63) Estimate
Portfolio Pulse from Benzinga Newsdesk
Soleno Therapeutics (NASDAQ:SLNO) reported a Q2 EPS of $(0.57), beating the analyst consensus estimate of $(0.63) by 9.52%. This represents a 29.63% improvement over the $(0.81) loss per share from the same period last year.
August 07, 2024 | 8:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Soleno Therapeutics reported a Q2 EPS of $(0.57), beating estimates and showing significant improvement from last year. This positive earnings surprise is likely to boost investor confidence in the short term.
The better-than-expected EPS and significant year-over-year improvement indicate strong performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100